SOPH

SOPH

USD

SOPHiA GENETICS SA Ordinary Shares

$3.160+0.060 (1.935%)

リアルタイム価格

Healthcare
Health Information Services
スイス

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$3.100

高値

$3.200

安値

$3.050

出来高

0.00M

企業ファンダメンタルズ

時価総額

211.2M

業種

Health Information Services

Switzerland

取引統計

平均出来高

0.06M

取引所

NMS

通貨

USD

52週レンジ

安値 $2.58現在値 $3.160高値 $6.28

AI分析レポート

最終更新: 2025年4月22日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

SOPH: SOPHiA GENETICS SA Ordinary Shares - Analyzing Recent Moves & What Might Come Next

Stock Symbol: SOPH Generate Date: 2025-04-22 20:48:14

Alright, let's break down what's been happening with SOPHiA GENETICS stock (SOPH) based on the latest info. We'll look at the news, the price chart, and what the AI model is predicting.

Recent News Buzz: What's the Vibe?

The main piece of news hitting the wires recently, specifically on April 8th, was about SOPHiA GENETICS teaming up with Precision for Medicine. This partnership is all about expanding services for biopharma companies, specifically using SOPHiA's DDM platform and its capabilities for analyzing liquid biopsies.

Think of it this way: SOPHiA has this cool software platform that helps analyze complex genetic data. Precision for Medicine helps drug companies develop and sell their products. By partnering, Precision for Medicine can now offer SOPHiA's advanced analysis tools to their drug company clients, especially for things like liquid biopsies (which are less invasive than traditional tissue biopsies).

The vibe from this news is definitely positive. It shows SOPHiA's technology is valuable enough for another player in the healthcare space to build services around it. It's a good sign for their platform's adoption and potential revenue down the line.

Price Check: What's the Stock Been Doing?

Looking at the price history over the last few months, it's been a bit of a rollercoaster, but the overall trend has been downwards since a peak in mid-February. The stock hit highs around $4.88 back then but has since drifted lower, recently touching lows around $2.58 in early April.

The current price is sitting around $2.91. So, it's bounced a little off those recent lows but is still significantly down from its earlier highs. The trading volume has been pretty inconsistent, sometimes seeing spikes (like in late January/mid-February and early March/late March), but often quite low, which is typical for smaller companies like this one.

Now, let's factor in the AI's short-term look ahead. The AI predicts a very slight dip today (-0.14%), but then sees positive movement for the next two days (+2.64% and +1.97%). This suggests the AI thinks the recent downward pressure might be easing, and there could be a small bounce coming up.

Putting It Together: Outlook & Strategy Ideas

Based on the positive news about the partnership, the stock price being near its recent lows, and the AI predicting a potential short-term upward move, the apparent near-term leaning here seems to be cautiously positive, perhaps leaning towards a 'hold' or a 'potential buy' for those comfortable with the risks.

Here's the thinking: The news is fundamentally good – it expands SOPHiA's reach and validates their technology. The price has been beaten down, which could mean it's undervalued if the company can execute on these partnerships and improve its financials over time. The AI's prediction of a bounce adds a short-term technical signal to consider.

Potential Entry Consideration: If you were thinking about this stock, the current price area, or perhaps a dip back towards the recent low or the AI's suggested support level around $2.73 or $2.82, might be areas to watch. The idea here is potentially getting in near a recent bottom if you believe the positive news and AI prediction signal a turning point. But remember, prices can always go lower.

Potential Exit/Stop-Loss Consideration: Managing risk is key. If you were to consider an entry, setting a stop-loss below a recent low, like the AI's suggested $2.50, could be a way to limit potential losses if the price continues to fall instead of bouncing. For potential upside, the AI suggests a take-profit level around $3.29. These are just potential guideposts based on the data provided.

Company Context

It's important to remember that SOPHiA GENETICS is a healthcare tech company focused on analyzing complex data using its software platform. The partnership news fits perfectly into their core business of working with biopharma companies. This isn't a huge company; it has a relatively small market capitalization and can have low trading volume, which often means the stock price can be quite volatile and move sharply on news or even small trading volumes. Also, the company's financials, like its negative P/E and ROE, and higher debt levels, are fundamental challenges to keep in mind despite the positive operational news and technical signals.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves significant risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

PR Newswire

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion ...

もっと見る
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
PR Newswire

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA...

もっと見る
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
PR Newswire

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA...

もっと見る
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

AI予測Beta

AI推奨

強気

更新日時: 2025年4月28日 12:23

弱気中立強気

62.2% 信頼度

リスクと取引

リスクレベル4/5
高リスク
適しているのは
バリュー
取引ガイド

エントリーポイント

$3.09

利確

$3.31

損切り

$2.79

主要因子

PDI 33.7はMDI 31.3の上にあり、ADX 14.9とともに強気トレンドを示唆しています
出来高は平均(1,560)の3.9倍で、極めて強い買い圧力を示しています
MACD 0.0355はシグナルライン0.0362の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。